These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 39083974

  • 1. Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation.
    Mao D, Guo J, Yang K, Yang F, Peng J, Jia X, Luo Z, Liu L, Yang E, Tang R, Lan H, Zheng Q.
    Biochem Biophys Res Commun; 2024 Nov 19; 734():150424. PubMed ID: 39083974
    [Abstract] [Full Text] [Related]

  • 2. Study on the action mechanism of the Polygonum perfoliatum L. on non-alcoholic fatty liver disease, based on network pharmacology and experimental validation.
    Liu G, Yang L, Tang Y, Lin J, Wang F, Shen J, Chang B, Kong X.
    J Ethnopharmacol; 2024 Jan 30; 319(Pt 3):117330. PubMed ID: 37863399
    [Abstract] [Full Text] [Related]

  • 3. Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4.
    Yang M, Yan R, Sha R, Wang X, Zhou S, Li B, Zheng Q, Cao Y.
    Clin Nutr; 2024 Aug 30; 43(8):1769-1780. PubMed ID: 38936303
    [Abstract] [Full Text] [Related]

  • 4. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
    Gan L, Meng ZJ, Xiong RB, Guo JQ, Lu XC, Zheng ZW, Deng YP, Luo BD, Zou F, Li H.
    Acta Pharmacol Sin; 2015 May 30; 36(5):597-605. PubMed ID: 25891086
    [Abstract] [Full Text] [Related]

  • 5. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet.
    Huang J, Li W, Liao W, Hao Q, Tang D, Wang D, Wang Y, Ge G.
    Food Funct; 2020 Nov 18; 11(11):9924-9935. PubMed ID: 33095225
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic Effect and Mechanism Prediction of Fuzi-Gancao Herb Couple on Non-alcoholic Fatty Liver Disease (NAFLD) based on Network Pharmacology and Molecular Docking.
    Liu K, Yang X, Zhang G, Xiang Z.
    Comb Chem High Throughput Screen; 2024 Nov 18; 27(5):773-785. PubMed ID: 37317908
    [Abstract] [Full Text] [Related]

  • 7. (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
    Ying L, Yan F, Zhao Y, Gao H, Williams BR, Hu Y, Li X, Tian R, Xu P, Wang Y.
    Clin Exp Pharmacol Physiol; 2017 Dec 18; 44(12):1180-1191. PubMed ID: 28815679
    [Abstract] [Full Text] [Related]

  • 8. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H, Tan H, Zhan W, Song L, Zhang D, Chen X, Lin Z, Wang W, Yang Y, Wang L, Bei W, Guo J.
    J Ethnopharmacol; 2021 Jun 28; 274():114056. PubMed ID: 33771638
    [Abstract] [Full Text] [Related]

  • 9. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization.
    Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C.
    Nutrients; 2021 Feb 11; 13(2):. PubMed ID: 33670347
    [Abstract] [Full Text] [Related]

  • 10. Exploring the effect and mechanism of Hippophae rhamnoides L. triterpenoid acids on improving NAFLD based on network pharmacology and experimental validation in vivo and in vitro.
    Ren L, Wang R, Wang Y, Tie F, Dong Q, Wang H, Hu N.
    J Ethnopharmacol; 2024 Dec 05; 335():118657. PubMed ID: 39127115
    [Abstract] [Full Text] [Related]

  • 11. Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway.
    Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, Xie Z, Ji A, Li Y.
    Oxid Med Cell Longev; 2021 Dec 05; 2021():5599997. PubMed ID: 33953830
    [Abstract] [Full Text] [Related]

  • 12. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice.
    Yang H, Wei D, Zhang Y, Jian W.
    Endocr Metab Immune Disord Drug Targets; 2024 Dec 05; 24(6):691-708. PubMed ID: 37859322
    [Abstract] [Full Text] [Related]

  • 13. Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.
    Chen C, Liu Q, Liu L, Hu YY, Feng Q.
    Mol Nutr Food Res; 2018 Jan 05; 62(1):. PubMed ID: 28799714
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment.
    Sun CY, Yang LL, Zhao P, Yan PZ, Li J, Zhao DS.
    Hereditas; 2022 Dec 01; 159(1):44. PubMed ID: 36451177
    [Abstract] [Full Text] [Related]

  • 15. Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway.
    Tian L, Chen J, Yang M, Chen L, Qiu J, Jiang Y, Tan X, Qian Q, Liang X, Dou X.
    Phytomedicine; 2024 Aug 01; 131():155776. PubMed ID: 38851104
    [Abstract] [Full Text] [Related]

  • 16. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
    Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL.
    Eur J Nutr; 2014 Feb 01; 53(1):187-99. PubMed ID: 23515587
    [Abstract] [Full Text] [Related]

  • 17. Prediction and verification of the active ingredients and potential targets of Erhuang Quzhi Granules on non-alcoholic fatty liver disease based on network pharmacology.
    Li S, Wu X, Ma Y, Zhang H, Chen W.
    J Ethnopharmacol; 2023 Jul 15; 311():116435. PubMed ID: 37023836
    [Abstract] [Full Text] [Related]

  • 18. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation.
    Zhang X, Gao R, Zhou Z, Sun J, Tang X, Li J, Zhou X, Shen T.
    J Ethnopharmacol; 2022 Oct 05; 296():115405. PubMed ID: 35644437
    [Abstract] [Full Text] [Related]

  • 19. A Study on the Therapeutic Efficacy of San Zi Yang Qin Decoction for Non-Alcoholic Fatty Liver Disease and the Underlying Mechanism Based on Network Pharmacology.
    Li Y, Liu Y, Yang M, Wang Q, Zheng Y, Xu J, Zheng P, Song H.
    Evid Based Complement Alternat Med; 2021 Oct 05; 2021():8819245. PubMed ID: 33505505
    [Abstract] [Full Text] [Related]

  • 20. Network analysis and experimental verification of Salvia miltiorrhiza Bunge-Reynoutria japonica Houtt. drug pair in the treatment of non-alcoholic fatty liver disease.
    Chen H, Yan S, Xiang Q, Liang J, Deng X, He W, Cheng Y, Yang L.
    BMC Complement Med Ther; 2024 Aug 14; 24(1):305. PubMed ID: 39143459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.